Bain Capital Life Sciences Investors, LLC's Form 4 filing
Kyverna Therapeutics, Inc.KYTX · filed Feb 14, 2024
- Accession no.
- 0000950170-24-015358
- Filed
- Feb 14, 2024, 5:26 PM ET
- Trade date
- Feb 12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $9.90M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bain Capital Life Sciences Investors, LLCCIK 0001703031 | 10% Owner |
| Bain Capital Life Sciences Fund III, L.P.CIK 0001875273 | 10% Owner |
| Bain Capital Life Sciences Opportunities III, LPCIK 0001950105 | 10% Owner |
| Bain Capital Life Sciences III General Partner, LLCCIK 0001952106 | 10% Owner |
| Bain Capital Life Sciences Opportunities III GP, LLCCIK 0001964467 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | Common Stock | CConversionAcquired | +2,713,868 | –F1 | – | 2,713,868 | Indirect | |
| Feb 12, 2024 | Common Stock | PPurchaseAcquired | +450,000 | $22.00 | +$9,900,000 | 3,163,868 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 12, 2024 | Common Stock | CConversionDisposed | −2,713,868 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each share of the Issuer's Series B Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock at a ratio of one-for-4.5511 immediately prior to the closing of the Issuer's initial public offering. These securities had no expiration date.
Referenced by the price of 1 transaction in Table I.